Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05882058` - DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers	Phase 2
Terminated	`NCT03963414` - A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC	Phase 1
Active, not recruiting	`NCT04358237` - Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.	Phase 1/Phase 2
Not yet recruiting	`NCT06419179` - Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)	Phase 2
Completed	`NCT02874664` - A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer	Phase 1
Completed	`NCT02397733` - Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)	N/A
Recruiting	`NCT01977235` - Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer	Phase 2
Completed	`NCT00759824` - A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide	Phase 2
Active, not recruiting	`NCT03568097` - Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer	Phase 2
Withdrawn	`NCT02876081` - Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex	Phase 2
Recruiting	`NCT06247605` - A Phase IIII Study of AL8326 in Small Cell Lung Cancer	Phase 3
Terminated	`NCT03662074` - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer	Phase 2
Completed	`NCT03232593` - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Completed	`NCT01941316` - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients	Phase 1/Phase 2
Terminated	`NCT01574300` - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Recruiting	`NCT06131840` - A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05683977` - A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Recruiting	`NCT04620837` - Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy	Phase 2
Recruiting	`NCT05329623` - A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.	Phase 1
Active, not recruiting	`NCT04902872` - Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors	Phase 1/Phase 2

NCT number	NCT04996771
Study type	Interventional
Source	Sun Yat-sen University
Contact	Wenfeng Fang, MD.
Phone	+86-15322302066
Email	fangwf@sysucc.org.cn
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	November 9, 2021
Completion date	December 31, 2024

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms